Access cutting-edge ovarian cancer treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.
Access ovarian cancer specialists in Anchorage at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ovarian cancer treatment provided free
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format
Sponsor: NRG Oncology
Check if you qualify for this ovarian cancer clinical trial in Anchorage, AK
If you're searching for ovarian cancer treatment options in Anchorage, AK, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.